Biopharma news, November 7, 2026
The most important drug and company news of November 7, 2026, ranked, each linked to its Gosset profiles.
Pivotal readout
Oral ICOTYDE hits phase 3 goal in biologic-naive psoriatic arthritis
Johnson & Johnson said 58% of adults with active psoriatic arthritis who had never taken a biologic reached ACR20 at week 16 on ICOTYDE, versus 41% on placebo. ACR50 rates were 29% and 16%, and skin measures also favored the oral peptide. No new safety signals emerged through week 24; the drug is not yet approved for this use.
Source types: Press release. Sources are available to Gosset users. Log in to see them.
Pivotal readout
Bayer reports Chinese subgroup data for asundexian in stroke prevention
Adding asundexian to antiplatelet therapy cut recurrent ischemic stroke by 32% among Chinese patients in the phase 3 OCEANIC-STROKE trial, with no rise in major bleeding. The global study of more than 12,000 patients showed a 26% reduction. Bayer said the Chinese findings match the overall results and that the drug is approved in China.
Source types: Press release. Sources are available to Gosset users. Log in to see them.
Clinical readout
J&J details patient priorities and saliva data for nipocalimab in Sjögren's
Exit interviews from DAHLIAS, a phase 2 trial, found dry mouth was the symptom patients most wanted improved. In an exploratory endpoint, 33% of patients on high-dose nipocalimab saw salivary flow rise by half or more at week 24, against 16% on placebo. Johnson & Johnson is running two phase 3 trials in the disease.
Source types: Press release. Sources are available to Gosset users. Log in to see them.
Discontinuation
Merck drops IL-2 agonist MK-1484 from its pipeline
Merck has stopped work on MK-1484, the IL-2 agonist it developed with Sutro Biopharma, citing a routine reshuffle of priorities. A second IL-2 asset, MK-6194, no longer appears on its public pipeline, leaving the company without an IL-2 program. Takeda and Innovent are still advancing TAK-928 in a global phase 3 lung cancer study.
Source types: News article. Sources are available to Gosset users. Log in to see them.
Clinical readout
Novo links Wegovy to liver and weight gains in real-world MASH studies
Two retrospective analyses tied Wegovy use in adults with MASH to larger drops in liver enzymes, weight and HbA1c. In one, patients lost an adjusted 18.9 lb over six months on Wegovy against 5.6 lb on resmetirom, though resmetirom cut LDL more. Neither study was randomized, so the results cannot show cause and effect.
Source types: Press release. Sources are available to Gosset users. Log in to see them.
Pivotal readout
argenx's VYVGART Hytrulo succeeds in phase 3 autoimmune myositis trial
In ALKIVIA, VYVGART Hytrulo improved the primary score by 15.4 points more than placebo at week 52 across necrotizing myopathy and dermatomyositis. The necrotizing myopathy group reached significance, while the smaller dermatomyositis group did not. argenx aims to file a US supplemental application in necrotizing myopathy by year-end.
Source types: Press release. Sources are available to Gosset users. Log in to see them.
Regulatory filing
China accepts zepuxitini filing in rheumatoid arthritis
China's drug evaluation center has accepted a marketing application for zepuxitini, a selective JAK1 inhibitor partnered by Simcere and Lingke, for active rheumatoid arthritis of moderate or severe grade. The filing rests on phase 3 data from 430 patients showing a significant edge over placebo, with responses holding to week 76. It is the drug's second Chinese filing after atopic dermatitis in April.
Source types: News article. Sources are available to Gosset users. Log in to see them.